This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Samson, R. Search for Related Content PubMed Articles by Samson, R. Social Bookmarking                         What's this?

Additive Benefits of Pravastatin and Aspirin to Decrease Risks of Cardiovascular Disease: Randomized and Observational Comparisons of Secondary Prevention Trials and Their Meta-analyses

Mote Vascular Foundation, 5741 Bee Ridge Road, #400, Sarasota, FL 34233 Rsamson{at}veinaindarteries.com

The authors investigated whether the antiatherogenic effects of pravastatin sodium and the antiplatelet effects of aspirin have additive clinical benefits. Meta-analyses were undertaken of the Long-Term Intervention With Pravastatin in lschaemic Disease trial and the Cholesterol and Recurrent Events trial to see if pravastatin and aspirin have additive benefits. Similar additive benefits of pravastatin and aspirin on cardiovascular disease were shown. The relative risk reduction with pravastatin and aspirin was 31% for myocardial infarction compared with aspirin alone and 26% compared with pravastatin alone. The authors concluded that increasing use of the combination to the current level of aspirin use would avoid large numbers of premature death.

Key Words: aspirin • pravastatin sodium • cardiovascular disease

Perspectives in Vascular Surgery and Endovascular Therapy, Vol. 17, No. 1, 65-1-67 (2005)
DOI: 10.1177/153100350501700115


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?